Opioids Drug Sales

Opioids Drug Sales Market Outlook

The global opioids drug sales market is projected to reach approximately USD 33 billion by 2035, expanding at a compound annual growth rate (CAGR) of 3.5% during the forecast period from 2025 to 2035. This growth is primarily driven by the increasing prevalence of chronic pain conditions and the rising geriatric population, which is more susceptible to pain-related disorders. Additionally, the evolving healthcare landscape, with enhanced access to healthcare services and a growing emphasis on pain management, has led to a surge in prescription opioid use. Despite the challenges posed by regulatory scrutiny and the opioid crisis, advancements in drug formulation and the development of new opioid products are expected to drive market expansion. Furthermore, the integration of technology in healthcare delivery is paving the way for more efficient pain management solutions, contributing positively to the market's growth trajectory.

Growth Factor of the Market

The growth of the opioids drug sales market is significantly influenced by several factors, including the high incidence of cancer and other chronic diseases which necessitate pain management therapies. A noteworthy trend is the increasing acceptance and adoption of opioids in various therapeutic areas such as oncology and palliative care. Moreover, the consolidation of pain management practices within healthcare facilities has spurred the demand for opioids in hospitals and clinics. Innovation in formulations that reduce the potential for misuse and addiction is also contributing to market growth, as it addresses the ongoing concerns regarding opioid abuse and dependency. Furthermore, the introduction of advanced delivery systems, such as transdermal patches and injectable formulations, has made opioids more accessible and effective for patients suffering from acute or chronic pain. Lastly, educational initiatives aimed at healthcare practitioners about the responsible prescribing of opioids are enhancing the overall market landscape.

Key Highlights of the Market

• The market is projected to reach USD 33 billion by 2035, with a CAGR of 3.5% from 2025 to 2035.
• Chronic pain conditions and the aging population are primary drivers of market growth.
• The integration of technology is enhancing pain management solutions.
• Innovations in opioid formulations are addressing concerns over misuse and addiction.
• Educational initiatives are promoting responsible opioid prescribing among healthcare practitioners.

By Product Type

Codeine:

Codeine, a naturally occurring opioid, is commonly used for the treatment of mild to moderate pain. It is also employed as a cough suppressant due to its ability to suppress the cough reflex. As one of the most widely prescribed opioids, codeine is often used in combination with other analgesics to enhance its effectiveness. The market for codeine remains robust, primarily driven by its lower addictive potential compared to stronger opioids, making it a preferred choice for managing pain in outpatient settings. However, the growing awareness of opioid misuse has led to increased scrutiny and regulations surrounding its prescription, which may impact its market share in the coming years.

Fentanyl:

Fentanyl is a powerful synthetic opioid that is used primarily for severe pain management, particularly in cancer patients and post-surgical care. Its potency is around 50 to 100 times greater than morphine, which allows for effective pain relief in smaller doses. The adoption of transdermal patches and injectable forms of fentanyl has significantly contributed to its market growth, as they provide sustained pain control for patients who require continuous analgesia. Despite its clinical utility, fentanyl's association with the opioid epidemic poses challenges, including increased regulation and public scrutiny regarding its safety. Consequently, while demand remains high, the market must navigate the complexities of regulatory compliance and misuse prevention.

Hydrocodone:

Hydrocodone is another widely prescribed opioid, often combined with acetaminophen or ibuprofen to treat moderate to severe pain. Its effectiveness in managing pain has solidified its presence in the market, making it one of the most frequently dispensed opioids in the United States. The rising prevalence of conditions such as arthritis and neuropathic pain has propelled the demand for hydrocodone in pain management. However, the increasing regulatory measures aimed at curbing opioid prescriptions may restrain its growth in the market. Additionally, awareness campaigns highlighting the risks associated with opioid abuse have prompted healthcare providers to reconsider prescribing practices, thereby influencing the hydrocodone market dynamics.

Oxycodone:

Oxycodone is a semi-synthetic opioid used to manage moderate to severe pain, particularly following surgery or in patients with chronic pain conditions. It is available in various formulations, including immediate-release and extended-release tablets, catering to different patient needs. The market for oxycodone has been bolstered by its widespread use in pain management protocols; however, it too faces the challenges associated with the opioid crisis. As misuse and addiction remain significant concerns, the regulatory landscape surrounding oxycodone has tightened, affecting its availability and prescribing patterns. Nevertheless, ongoing research and development efforts aimed at creating abuse-deterrent formulations are expected to revitalize the oxycodone market, providing safer options for pain relief.

Morphine:

Morphine is a classic opioid used for severe pain management, particularly in terminally ill patients and those undergoing major surgeries. Its long-standing presence in the pharmaceutical market underscores its efficacy as an analgesic. Morphine's ability to provide profound pain relief makes it a cornerstone in palliative care and cancer therapy. However, like other opioids, it is subject to strict regulations due to its potential for abuse and addiction. The market for morphine is influenced by factors such as the increasing emphasis on end-of-life care and the growing need for effective pain management solutions in various healthcare settings. Innovations in morphine delivery methods, such as controlled-release formulations, are further enhancing its application in clinical practice.

By Application

Pain Management:

Pain management is the leading application segment for opioids, driven by the rising prevalence of chronic pain disorders such as arthritis, fibromyalgia, and back pain. Patients suffering from these conditions often rely on opioid medications to alleviate their discomfort and improve their quality of life. The growing body of research supporting opioid efficacy in pain alleviation has contributed to the segment's robust growth. Moreover, the increasing acceptance of opioids in both acute and chronic pain management protocols by healthcare professionals is further propelling market demand. As healthcare systems evolve to prioritize comprehensive pain management strategies, opioids are likely to remain a critical component in treating pain effectively.

Anesthesia:

Opioids play a pivotal role in anesthesia, as they are often utilized as part of preoperative and postoperative pain management protocols. These medications provide significant analgesic effects, allowing for smoother surgical procedures and improving patient comfort during recovery. The opioid's ability to decrease the amount of general anesthesia required further enhances its value in surgical settings. As surgical procedures become more complex and prevalent, the demand for opioids within anesthesia applications is expected to grow. However, the increasing concerns around opioid-related adverse effects and addiction are prompting the development of alternative anesthetic agents, which may impact the market dynamics in this segment.

Cough Suppression:

The application of opioids for cough suppression is a well-established practice, particularly with products containing codeine. Opioids act on the central nervous system to suppress the cough reflex, making them effective for treating chronic cough conditions, such as those associated with respiratory infections. The market for cough suppressants that utilize opioids is influenced by the rising incidence of respiratory diseases and allergies. However, the growing awareness of the risks associated with opioid use, especially in non-essential applications like cough suppression, has led to increased scrutiny and recommendations for alternative treatments. As healthcare providers seek to balance effective treatment with safety, the market for opioids in cough suppression may face challenges moving forward.

Diarrhea Treatment:

Opioids are also used in the treatment of diarrhea, particularly in cases of severe or chronic forms such as those seen in irritable bowel syndrome. Medications such as loperamide, a derivative of opioids, are utilized for their ability to slow gut motility and improve stool consistency. This application segment benefits from the increasing prevalence of gastrointestinal disorders, which drives demand for effective treatment options. While the market for opioids in diarrhea treatment is relatively smaller compared to pain management, it remains significant, particularly in specialized medical practices. The market's growth is supported by ongoing research and development efforts focused on improving the efficacy and safety profiles of opioid-based treatments for diarrhea.

Others:

The 'Others' application segment encompasses various uses of opioids beyond pain management, anesthesia, cough suppression, and diarrhea treatment. This may include their role in treating substance use disorders and managing withdrawal symptoms. The versatility of opioids contributes to this segment's growth, as they are employed in different therapeutic areas depending on clinical needs. The awareness and acknowledgment of opioids in these applications are gradually increasing, supported by research highlighting their importance in comprehensive treatment strategies. However, as the opioid crisis continues to affect public perception, the development of non-opioid alternatives in these applications may shape the future landscape of this segment.

By Distribution Channel

Hospitals:

Hospitals are a significant distribution channel for opioids, as they are integral to pain management protocols in surgical and critical care settings. The demand for opioids in hospitals is primarily driven by the need for effective analgesia during and after surgical procedures. Hospitals often utilize a variety of opioid formulations, including intravenous and injectable options, to ensure rapid onset and effective pain control. The market in this channel is bolstered by an increasing number of surgical procedures, alongside a growing emphasis on patient-centered care and pain management excellence. However, stringent regulations and procurement challenges can impact pricing and availability, necessitating careful management within hospital systems to balance opioid use with safety concerns.

Retail Pharmacies:

Retail pharmacies serve as a critical distribution channel for opioids, providing patients with access to prescribed medications for chronic pain management and other conditions. The convenience and availability of opioids in retail settings contribute to their widespread use among patients. This segment benefits from the overall growth of the retail pharmacy industry and the increasing number of prescriptions written for opioids. However, the rise of prescription monitoring programs and stricter regulations regarding opioid dispensing are shaping the operational landscape for retail pharmacies. As a result, pharmacies must implement robust compliance measures to ensure responsible dispensing and mitigate the risks associated with opioid misuse within their communities.

Online Pharmacies:

The emergence of online pharmacies has transformed the distribution channel for opioids, allowing for more accessible and convenient access to medications for patients. This segment has gained traction, particularly during the COVID-19 pandemic, as patients sought alternatives to in-person pharmacy visits. Online pharmacies can provide a wider selection of opioid formulations, often at competitive prices, appealing to patients managing chronic pain. However, the online distribution of opioids presents challenges, including ensuring regulatory compliance and combating counterfeit medications. As e-commerce continues to grow, the market dynamics in this segment will increasingly depend on the ability of online pharmacies to promote safe practices and build trust with consumers.

Drug Stores:

Drug stores play an essential role in opioid distribution, often serving as primary locations for patients to fill prescriptions for pain management. These establishments typically offer a range of opioid products, catering to the diverse needs of patients. The ease of access to opioids in drug stores contributes to their significant market share within the distribution channel segment. Moreover, drug stores often provide additional services, such as counseling and medication management programs, which can enhance patient compliance and safety. However, similar to retail pharmacies, drug stores are also navigating the challenges posed by increased scrutiny on opioid prescriptions, leading to potential shifts in dispensing practices.

Others:

The 'Others' distribution channel category encompasses various alternative outlets through which opioids may be dispensed, including specialty pharmacies, compounding pharmacies, and clinics. Specialty pharmacies, for instance, focus on providing medications for specific health conditions, including pain management, which can lead to tailored treatment approaches for patients. Compounding pharmacies may offer customized formulations of opioids for patients with unique needs. Clinics that specialize in pain management may also serve as distribution points, allowing for a comprehensive approach to patient care. While these alternative channels are not as prominent as hospitals or retail pharmacies, they are important for ensuring that patients have access to the opioid medications they require.

By Ingredient Type

Natural Opioids:

Natural opioids, derived from the opium poppy, include well-known substances such as morphine and codeine. These compounds have been utilized for centuries in medicine for their potent analgesic properties. The market for natural opioids continues to hold significance, particularly due to their effectiveness in managing severe pain. As healthcare providers increasingly prioritize the use of established therapies in pain management, the role of natural opioids remains vital. However, the potential for addiction and the regulatory scrutiny surrounding their use necessitate careful consideration by prescribers. Innovations aimed at improving the safety profile of natural opioids may enhance their role in contemporary medical practice.

Semi-Synthetic Opioids:

Semi-synthetic opioids, such as oxycodone and hydrocodone, are chemically modified derivatives of natural opioids. These drugs have been designed to enhance efficacy and reduce side effects while maintaining the pain-relieving properties of their natural counterparts. The market for semi-synthetic opioids is expanding, driven by their widespread use in pain management and prescription practices. Their ability to provide effective relief for moderate to severe pain has made them popular among healthcare providers. Nevertheless, the potential for misuse and addiction remains a concern, prompting ongoing research into safety measures and alternative therapies to mitigate these risks within this segment.

Fully Synthetic Opioids:

Fully synthetic opioids, such as fentanyl and methadone, are engineered in laboratories to produce potent analgesic effects. These compounds are particularly valuable in managing severe pain, especially in patients with cancer or those undergoing major surgical procedures. The market for fully synthetic opioids has seen notable growth owing to their effectiveness and the ability to tailor formulations for specific clinical needs. However, the rise in illicitly manufactured synthetic opioids, particularly fentanyl, raises significant public health concerns related to overdose and addiction. As such, the regulatory landscape surrounding fully synthetic opioids is evolving, with a focus on balancing patient access with safety measures to mitigate risks associated with these powerful medications.

By Region

The North American region dominates the opioids drug sales market, accounting for a significant share due to the high prevalence of chronic pain and a well-established healthcare infrastructure. The market in North America is projected to reach approximately USD 20 billion by 2035, growing at a CAGR of 3.8% during the forecast period. The United States, in particular, remains the largest consumer of opioids globally, with a substantial number of prescriptions written for these medications. However, the ongoing opioid crisis has led to increased regulatory scrutiny and changes in prescribing practices, which may impact market growth. The necessity for stricter regulations is also reflected in the growing emphasis on responsible prescribing and the development of abuse-deterrent formulations. This complex landscape presents both challenges and opportunities for stakeholders within the region.

Europe is also a crucial market for opioids, expected to reach approximately USD 9 billion by 2035, with a CAGR of 3.2% during the forecast period. The increasing focus on pain management and palliative care within European healthcare systems is driving demand for opioids. Several countries are implementing guidelines to ensure the responsible use of opioids, balancing accessibility with the need to address concerns about addiction and misuse. The ongoing collaboration between healthcare professionals and regulatory authorities is essential for ensuring that opioid medications are used effectively and safely. As more countries in Europe recognize the importance of pain management, the opioids market in the region is likely to continue its growth trajectory while addressing the challenges posed by the opioid crisis.

Opportunities

The opioids drug sales market presents several lucrative opportunities for growth, particularly through the development of innovative formulations and delivery systems. Pharmaceutical companies are increasingly investing in research and development to create abuse-deterrent formulations that mitigate the risks of misuse and addiction associated with traditional opioids. These advancements are critical for restoring public trust in opioids as safe and effective pain management options. Additionally, the growing focus on personalized medicine opens avenues for tailored opioid therapies that consider individual patient factors, enhancing efficacy while minimizing adverse effects. As healthcare providers continue to seek effective pain management strategies, opportunities abound for companies that can develop novel solutions that prioritize patient well-being.

Moreover, the increasing awareness of chronic pain management as a critical aspect of healthcare is driving demand for opioids across various therapeutic areas. The expansion of pain management clinics and the emphasis on multidisciplinary approaches to pain treatment further create opportunities within the market. As healthcare systems worldwide recognize the importance of addressing pain effectively, there is potential for greater integration of opioids into comprehensive treatment plans. This evolving landscape encourages collaboration between pharmaceutical companies, healthcare practitioners, and regulatory bodies, fostering an environment conducive to innovation and improved patient outcomes.

Threats

The threats facing the opioids drug sales market are largely rooted in the ongoing opioid crisis, which has generated significant public and regulatory scrutiny. Concerns about opioid addiction and overdose have led to stricter prescribing guidelines and heightened awareness of the risks associated with opioid use. These factors can hinder market growth, as healthcare providers may be more hesitant to prescribe opioids, especially for chronic pain management. Additionally, the rise of non-opioid alternatives for pain management further complicates the market landscape, as patients and providers increasingly seek safer options. The challenge for the industry lies in balancing the need for effective pain relief with the imperative to address the risks of opioid misuse and addiction.

Moreover, regulatory pressures and the potential for litigation against pharmaceutical companies involved in the opioid supply chain pose significant threats to the market. The increasing number of lawsuits filed against companies for their role in fueling the opioid epidemic has resulted in substantial financial liabilities and reputational damage. This environment of heightened accountability may discourage investment in opioid development and lead to a reduction in the availability of opioid medications. As the industry navigates these threats, it will be essential for companies to adopt responsible practices and engage in proactive communications with stakeholders to rebuild trust and ensure the sustainable provision of pain management solutions.

Competitor Outlook

• Purdue Pharma
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Mallinckrodt Pharmaceuticals
• Pfizer Inc.
• AbbVie Inc.
• Endo International plc
• Amgen Inc.
• Hikma Pharmaceuticals
• Gilead Sciences
• Sun Pharmaceutical Industries
• Alkermes plc
• Insys Therapeutics
• Novartis AG
• Opiant Pharmaceuticals

The competitive landscape of the opioids drug sales market is characterized by the presence of several key players who are actively engaged in the development and distribution of opioid medications. These companies are navigating a complex environment shaped by regulatory challenges and public perception of opioids. Major pharmaceutical firms, such as Purdue Pharma and Johnson & Johnson, have historically dominated the market due to their extensive portfolios of opioid products. However, the opioid crisis has compelled these companies to reevaluate their strategies and invest in the development of safer, abuse-deterrent formulations to address the growing concerns surrounding opioid misuse.

Teva Pharmaceutical Industries and Mallinckrodt Pharmaceuticals are also significant players in the opioids market, contributing to the diverse range of opioid medications available to healthcare providers. These companies are leveraging their expertise in pharmaceuticals to innovate and offer products that meet the evolving needs of patients. Additionally, firms like Pfizer Inc. and AbbVie Inc. are exploring new delivery mechanisms and formulations that enhance the safety and efficacy of opioids while minimizing the risk of addiction. As the market continues to evolve, these companies will need to remain agile and responsive to both regulatory changes and shifts in consumer preferences.

Furthermore, emerging companies, such as Opiant Pharmaceuticals, are positioning themselves to capitalize on opportunities within the opioids market by focusing on the development of treatments for opioid use disorder and related conditions. The increasing emphasis on comprehensive pain management and addiction treatment presents growth potential for companies that can successfully address these critical areas. The competitive landscape will undoubtedly continue to shift as companies adapt to the challenges and opportunities presented by the opioid crisis and the demand for effective pain management solutions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Alkermes plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Purdue Pharma
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Gilead Sciences
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Insys Therapeutics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hikma Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Endo International plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Opiant Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Mallinckrodt Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Opioids Drug Sales Market, By Application
    • 6.1.1 Pain Management
    • 6.1.2 Anesthesia
    • 6.1.3 Cough Suppression
    • 6.1.4 Diarrhea Treatment
    • 6.1.5 Others
  • 6.2 Opioids Drug Sales Market, By Product Type
    • 6.2.1 Codeine
    • 6.2.2 Fentanyl
    • 6.2.3 Hydrocodone
    • 6.2.4 Oxycodone
    • 6.2.5 Morphine
  • 6.3 Opioids Drug Sales Market, By Ingredient Type
    • 6.3.1 Natural Opioids
    • 6.3.2 Semi-Synthetic Opioids
    • 6.3.3 Fully Synthetic Opioids
  • 6.4 Opioids Drug Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Opioids Drug Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Opioids Drug Sales market is categorized based on

By Product Type

• Codeine
• Fentanyl
• Hydrocodone
• Oxycodone
• Morphine

By Application

• Pain Management
• Anesthesia
• Cough Suppression
• Diarrhea Treatment
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Natural Opioids
• Semi-Synthetic Opioids
• Fully Synthetic Opioids

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Purdue Pharma
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Mallinckrodt Pharmaceuticals
• Pfizer Inc.
• AbbVie Inc.
• Endo International plc
• Amgen Inc.
• Hikma Pharmaceuticals
• Gilead Sciences
• Sun Pharmaceutical Industries
• Alkermes plc
• Insys Therapeutics
• Novartis AG
• Opiant Pharmaceuticals